Newbury Pharmaceuticals AB (publ) (OM: NEWBRY)
Health Care · Pharmaceuticals · SE
Skr2.44
-10.29% today · +5.0% 1Y
Newbury Pharmaceuticals AB (publ) (OM: NEWBRY) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $8.69M and employs 7 people.
Over the last twelve months the share price has gained 5.0%, trading between 0.76 and 7.88.
Tweenvest scores Newbury Pharmaceuticals AB (publ) across four factors: quality 38/100, value 41/100. Its strongest factor is value.
NEWBRY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.69M
- Revenue (TTM)
- $3.80M
- P/E
- —
- EPS
- -0.89
- Dividend yield
- —
- Beta (5Y)
- 1.26
- 52-week high
- Skr7.88
- 52-week low
- Skr0.76
- Avg volume (3M)
- —
- Shares outstanding
- 30.40M
- Employees
- 7
- Next earnings
- —
About Newbury Pharmaceuticals AB (publ)
Newbury Pharmaceuticals AB (publ), a hybrid pharmaceutical enterprise, serves both the Swedish and wider Scandinavian markets. Formed in 2020 and headquartered in Lund, Sweden, the company provides a variety of therapeutic solutions, with a strong emphasis on oncology, rare diseases, and neurology, in addition to other treatment categories.
- ISIN
- SE0015244884
- Founded
- 2020
- Listed since
- Feb 4, 2022
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.11T | $1,246.93 | -0.67% |
| Johnson & JohnsonNYSE: JNJ | $658.00B | $273.04 | +1.04% |
| Merck & Co., Inc.NYSE: MRK | $371.70B | $150.66 | -1.24% |
| Roche Holding AGSWX: ROP | $368.80B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $300.52B | CHF126.76 | -0.52% |
| AstraZeneca PLCLSE: AZN | $256.25B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $206.64B | Dkr299.25 | -0.53% |
| Pfizer Inc.NYSE: PFE | $159.42B | $27.97 | -0.36% |
Figures last refreshed Aug 18, 2026.